Valganciclovir in an antibody-selected CFS subgroup
Montoya JG et al. · 2013 · Journal of Medical Virology
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Double-blind six-month course of valganciclovir or placebo, with fatigue and cognitive outcomes followed over time.
Dose, route and schedule
Double-blind six-month course of valganciclovir or placebo, with fatigue and cognitive outcomes followed over time.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total multidimensional fatigue score | The between-group difference at nine months was inconclusive. | |
| Secondary symptom trajectories | Mental fatigue (p=0.039), Fatigue Severity Scale (p=0.006) and cognitive function (p=0.025) favored valganciclovir over time. |
The sample was small and selected by antibody titers. Elevated IgG alone does not demonstrate active viral replication.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The sample was small and selected by antibody titers. Elevated IgG alone does not demonstrate active viral replication.
Source access
Double-blind six-month course of valganciclovir or placebo, with fatigue and cognitive outcomes followed over time.
Source reviewed 2026-11-12.
DOI: 10.1002/jmv.23713
Citation and original source
Original source: Montoya JG et al.. Valganciclovir in an antibody-selected CFS subgroup Journal of Medical Virology 2013.
Molekul research summary: https://molekul.io/research/valganciclovir-montoya-2013. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry